COVID-19 early treatment: real-time analysis of 5,255 studies
Atieh | RCT 151 long COVID outpatients showing improved long COVID Research Index, number of symptoms, inflammatory markers, and fungal translocation with.. |
Bramante | 2,991 patient metformin late treatment RCT: 24% higher progression (p=0.28) and 4% worse recovery (p=0.28) |
Voloudakis | 755,346 patients vitamin A prophylaxis: 19% fewer cases (p=0.0008) |
Timeline for when studies showed efficacy - details and limitations.
0.5% of treatments show efficacy.
Top journals that accept positive studies for low cost treatments:
Nutrients,
PLOS ONE,
Journal of Clinical Medicine,
International Journal of Infectious Diseases,
Scientific Reports,
Cureus,
more...
Treatment cost times median NNT - details and limitations.
0.5% of treatments show efficacy.
Loading..
All clinical results for selected treatments. 0.5% of treatments show efficacy.
Loading..
Random effects meta-analysis of all studies (pooled effects, all stages). Treatments with ≤3 studies with distinct authors or with <50 control events are shown in grey. Pooled results across all stages and outcomes depend on the distribution of stages and outcomes tested - for example late stage treatment may be less effective and if the majority of studies are late stage this may obscure the efficacy of early treatment. Please see the specific stage and outcome analyses. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. | |||||
Loading.. Loading.. | |||||
Random effects meta-analysis of early treatment studies (pooled effects). Treatments with ≤3 studies with distinct authors or with <50 control events are shown in grey. Pooled results across all outcomes are affected by the distribution of outcomes tested, please see detail pages for specific outcome analysis. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. | |||||
Loading.. Loading.. | |||||
Random effects meta-analysis of all mortality results (all stages). Treatments with ≤3 studies with distinct authors or with <25 control events are shown in grey. Pooled results across all stages depend on the distribution of stages tested - for example late stage treatment may be less effective and if the majority of studies are late stage this may obscure the efficacy of early treatment. Please see the specific stage analyses. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. | |||||
Loading.. Loading.. | |||||
Random effects meta-analysis of early treatment mortality results. Treatments with ≤3 studies with distinct authors or with <25 control events are shown in grey. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. | |||||
Loading.. Loading.. | |||||
Random effects meta-analysis of prophylaxis studies (pooled effects). Treatments with ≤3 studies with distinct authors or with <50 control events are shown in grey. Pooled results across all outcomes are affected by the distribution of outcomes tested, please see detail pages for specific outcome analysis. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. | |||||
Loading.. Loading.. | |||||
Random effects meta-analysis of prophylaxis mortality results. Treatments with ≤3 studies with distinct authors or with <25 control events are shown in grey. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. | |||||
Loading.. Loading.. | |||||
Random effects meta-analysis of long covid results. Treatments with ≤3 studies with distinct authors or with <50 control events are shown in grey. Pooled results across all stages and outcomes depend on the distribution of stages and outcomes tested - for example late stage treatment may be less effective and if the majority of studies are late stage this may obscure the efficacy of early treatment. Please see the specific stage and outcome analyses. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. | |||||
Loading.. Loading.. | |||||
Random effects meta-analysis of transmission results. Treatments with ≤3 studies with distinct authors or with <50 control events are shown in grey. Pooled results across all stages and outcomes depend on the distribution of stages and outcomes tested - for example late stage treatment may be less effective and if the majority of studies are late stage this may obscure the efficacy of early treatment. Please see the specific stage and outcome analyses. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. |
LATE TREATMENT | ||||||
Physician / Team | Location | Patients | HospitalizationHosp. | MortalityDeath | ||
Dr. David Uip (*) | Brazil | 2,200 | 38.6% (850) | Ref. | 2.5% (54) | Ref. |
EARLY TREATMENT - 40 physicians/teams | ||||||
Physician / Team | Location | Patients | HospitalizationHosp. | ImprovementImp. | MortalityDeath | ImprovementImp. |
Dr. Roberto Alfonso Accinelli 0/360 deaths for treatment within 3 days |
Peru | 1,265 | 0.6% (7) | 77.5% | ||
Dr. Mohammed Tarek Alam patients up to 84 years old |
Bangladesh | 100 | 0.0% (0) | 100.0% | ||
Dr. Oluwagbenga Alonge | Nigeria | 310 | 0.0% (0) | 100.0% | ||
Dr. Raja Bhattacharya up to 88yo, 81% comorbidities |
India | 148 | 1.4% (2) | 44.9% | ||
Dr. Flavio Cadegiani | Brazil | 3,450 | 0.1% (4) | 99.7% | 0.0% (0) | 100.0% |
Dr. Alessandro Capucci | Italy | 350 | 4.6% (16) | 88.2% | ||
Dr. Shankara Chetty | South Africa | 8,000 | 0.0% (0) | 100.0% | ||
Dr. Deborah Chisholm | USA | 100 | 0.0% (0) | 100.0% | ||
Dr. Ryan Cole | USA | 400 | 0.0% (0) | 100.0% | 0.0% (0) | 100.0% |
Dr. Marco Cosentino vs. 3-3.8% mortality during period; earlier treatment better |
Italy | 392 | 6.4% (25) | 83.5% | 0.3% (1) | 89.6% |
Dr. Jeff Davis | USA | 6,000 | 0.0% (0) | 100.0% | ||
Dr. Dhanajay | India | 500 | 0.0% (0) | 100.0% | ||
Dr. Bryan Tyson & Dr. George Fareed | USA | 20,000 | 0.0% (6) | 99.9% | 0.0% (4) | 99.2% |
Dr. Raphael Furtado | Brazil | 170 | 0.6% (1) | 98.5% | 0.0% (0) | 100.0% |
Rabbi Yehoshua Gerzi | Israel | 860 | 0.1% (1) | 99.7% | 0.0% (0) | 100.0% |
Dr. Heather Gessling | USA | 1,500 | 0.1% (1) | 97.3% | ||
Dr. Ellen Guimarães | Brazil | 500 | 1.6% (8) | 95.9% | 0.4% (2) | 83.7% |
Dr. Syed Haider | USA | 4,000 | 0.1% (5) | 99.7% | 0.0% (0) | 100.0% |
Dr. Mark Hancock | USA | 24 | 0.0% (0) | 100.0% | ||
Dr. Sabine Hazan | USA | 1,000 | 0.0% (0) | 100.0% | ||
Dr. Mollie James | USA | 3,500 | 1.1% (40) | 97.0% | 0.0% (1) | 98.8% |
Dr. Roberta Lacerda | Brazil | 550 | 1.5% (8) | 96.2% | 0.4% (2) | 85.2% |
Dr. Katarina Lindley | USA | 100 | 5.0% (5) | 87.1% | 0.0% (0) | 100.0% |
Dr. Ben Marble | USA | 150,000 | 0.0% (4) | 99.9% | ||
Dr. Edimilson Migowski | Brazil | 2,000 | 0.3% (7) | 99.1% | 0.1% (2) | 95.9% |
Dr. Abdulrahman Mohana | Saudi Arabia | 2,733 | 0.0% (0) | 100.0% | ||
Dr. Carlos Nigro | Brazil | 5,000 | 0.9% (45) | 97.7% | 0.5% (23) | 81.3% |
Dr. Benoit Ochs | Luxembourg | 800 | 0.0% (0) | 100.0% | ||
Dr. Ortore | Italy | 240 | 1.2% (3) | 96.8% | 0.0% (0) | 100.0% |
Dr. Valerio Pascua one death for a patient presenting on the 5th day in need of supplemental oxygen |
Honduras | 415 | 6.3% (26) | 83.8% | 0.2% (1) | 90.2% |
Dr. Sebastian Pop | Romania | 300 | 0.0% (0) | 100.0% | ||
Dr. Brian Proctor | USA | 869 | 2.3% (20) | 94.0% | 0.2% (2) | 90.6% |
Dr. Anastacio Queiroz | Brazil | 700 | 0.0% (0) | 100.0% | ||
Dr. Didier Raoult | France | 8,315 | 2.6% (214) | 93.3% | 0.1% (5) | 97.6% |
Dr. Karin Ried up to 99yo, 73% comorbidities, av. age 63 |
Turkey | 237 | 0.4% (1) | 82.8% | ||
Dr. Roman Rozencwaig patients up to 86 years old |
Canada | 80 | 0.0% (0) | 100.0% | ||
Dr. Vipul Shah | India | 8,000 | 0.1% (5) | 97.5% | ||
Dr. Silvestre Sobrinho | Brazil | 116 | 8.6% (10) | 77.7% | 0.0% (0) | 100.0% |
Dr. Unknown | Brazil | 957 | 1.7% (16) | 95.7% | 0.2% (2) | 91.5% |
Dr. Vladimir Zelenko | USA | 2,200 | 0.5% (12) | 98.6% | 0.1% (2) | 96.3% |
Mean improvement with early treatment protocols | 238,381 | HospitalizationHosp. | 94.4% | MortalityDeath | 94.9% |
Physician results with early treatment protocols compared to
no early treatment. These results are subject to selection and ascertainment
bias and more accurate analysis requires details of the patient populations
and followup, however results are consistently better across many teams, and consistent
with the extensive controlled trial evidence that shows a significant
reduction in risk with many early treatments, and improved results with the
use of multiple treatments in combination.
Atieh | RCT 151 long COVID outpatients showing improved long COVID Research Index, number of symptoms, inflammatory markers, and fungal translocation with.. |
Atieh | RCT 151 long COVID outpatients showing improved long COVID Research Index, number of symptoms, inflammatory markers, and fungal translocation with.. |
Bramante | 2,991 patient late treatment RCT: 24% higher progression (p=0.28) and 4% worse recovery (p=0.28) |
Benfathallah | 115 patients prophylaxis: 54% lower mortality (p=0.04) |
Halabitska | Review of metformin as a promising broad-spectrum antiviral agent, focusing on its potential for treating SARS-CoV-2 infection. Authors highlight.. |
Voloudakis | 755,346 patients prophylaxis: 19% fewer cases (p=0.0008) |
Hemilä | Review of vitamin C for the common cold and pneumonia. Authors conclude that while regular vitamin C supplementation does not prevent common colds.. |
Hamdan | In Silico study showing that H1RA antihistamines, including bilastine, fexofenadine, mizolastine, rupatadine, terfenadine, and the leukotriene.. |
Hamdan | In Silico study showing that H1RA antihistamines, including bilastine, fexofenadine, mizolastine, rupatadine, terfenadine, and the leukotriene.. |
Raval | Meta-analysis showing significantly higher COVID-19 mortality and symptomatology with zinc deficiency. |
Songvut | Analysis of the pharmacokinetics and safety of high-dose Andrographis paniculata ethanolic extract. Authors observed non-linear oral bioavailability.. |
Hu | Phase 1 dose-escalation trial of 80 healthy volunteers showing favorable safety, tolerability, nasal retention, and neutralizing activity with a.. |
Duan | Review of how bioactive compounds quercetin, curcumin, and β-glucan regulate innate immunity through the gut-liver-brain axis, with focus on COVID.. |
Duan | Review of how bioactive compounds quercetin, curcumin, and β-glucan regulate innate immunity through the gut-liver-brain axis, with focus on COVID.. |
Yu | Retrospective 5,131 elderly hospitalized COVID-19 patients in China showing lower mortality with azvudine compared to paxlovid. There was no.. |
Yu | Retrospective 5,131 elderly hospitalized COVID-19 patients in China showing lower mortality with azvudine compared to paxlovid. There was no.. |
Recent studies (see the individual treatment pages for all studies):
Jan 16 |
et al., Life, doi:10.3390/life15010113 | Immune-Boosting and Antiviral Effects of Antioxidants in COVID-19 Pneumonia: A Therapeutic Perspective |
Review of immune-boosting and antiviral effects of antioxidants in COVID-19 pneumonia. Authors provide an overview of the literature on the use of antioxidants, including vitamins, trace elements, ozone, glutathione, L-carnitine, melatoni.. | ||
Jan 14 |
et al., medRxiv, doi:10.1101/2025.01.13.25320485 | Metformin on Time to Sustained Recovery in Adults with COVID-19: The ACTIV-6 Randomized Clinical Trial |
24% higher progression (p=0.28) and 4% worse recovery (p=0.28). RCT 2,991 outpatient adults with mild to moderate COVID-19 showing no significant difference in time to sustained recovery with metformin compared to placebo. Median days to symptom resolution was 9 days vs. 10 days for placebo, without s.. | ||
Jan 14 |
et al., medRxiv, doi:10.1101/2025.01.10.25320348 | A genetically based computational drug repurposing framework for rapid identification of candidate compounds: application to COVID-19 |
19% fewer cases (p=0.0008). Computational drug repurposing study integrating genetically regulated gene expression (GReX) and pharmaceutical databases to identify 7 FDA-approved compounds that may reverse COVID-19-related gene expression. Analysis of 755,346 people .. | ||
Jan 13 |
et al., Polish Archives of Internal Medicine, doi:10.20452/pamw.16926 | Vitamin C for the common cold and pneumonia |
Review of vitamin C for the common cold and pneumonia. Authors conclude that while regular vitamin C supplementation does not prevent common colds infections in the general population, it significantly reduces the severity and duration of.. | ||
Jan 11 |
et al., Cureus, doi:10.7759/cureus.77288 | Does the Consumption of Metformin Correlate With a Reduction in Mortality Among Patients With Type 2 Diabetes and COVID-19 in Morocco? |
54% lower mortality (p=0.04). Retrospective 115 hospitalized type 2 diabetes patients in Morocco showing significantly lower mortality with metformin use. | ||
Jan 10 |
et al., Turkish Journal of Pharmaceutical Sciences, doi:10.4274/tjps.galenos.2024.49768 | In silico Evaluation of H1-Antihistamine as Potential Inhibitors of SARS-CoV-2 RNA-dependent RNA Polymerase: Repurposing Study of COVID-19 Therapy |
In Silico study showing that H1RA antihistamines, including bilastine, fexofenadine, mizolastine, rupatadine, terfenadine, and the leukotriene receptor antagonists montelukast and zafirlukast, may inhibit SARS-CoV-2 RNA-dependent RNA poly.. | ||
Jan 9 |
, R., Cureus, doi:10.7759/cureus.77188 | COVID-19 Humic/Fulvic Acid Plus Epigallocatechin Gallate Treatment: A Retrospective Chart Review |
97% lower mortality (p<0.0001). Retrospective 60 COVID-19 patients in a nursing home facility showing no mortality with EGCG (from green tea extract), humic/fulvic acid, and vitamin C treatment, compared to 55% mortality in the control group not receiving treatment. | ||
Jan 6 |
et al., Pharmaceutical Biology, doi:10.1080/13880209.2024.2444446 | Non-linear oral bioavailability and clinical pharmacokinetics of high-dose Andrographis paniculata ethanolic extract: relevant dosage implications for COVID-19 treatment |
Analysis of the pharmacokinetics and safety of high-dose Andrographis paniculata ethanolic extract. Authors observed non-linear oral bioavailability, with low plasma concentrations of key bioactive diterpenoids following ethanolic extract.. | ||
Jan 6 |
et al., Cureus, doi:10.7759/cureus.77011 | Zinc Deficiency Associated With an Increase in Mortality in COVID-19 Patients: A Meta-Analysis |
Meta-analysis showing significantly higher COVID-19 mortality and symptomatology with zinc deficiency. | ||
Dec 31 |
et al., Melatonin Research, doi:10.32794/mr112500181 | Potential therapeutic intervention of melatonin against COVID-19: A comparative pharmacokinetic study |
In Silico study showing that melatonin may be beneficial for COVID-19 compared to methylprednisolone, doxycycline, oseltamivir, and remdesivir. Authors find that melatonin has superior pharmacokinetic properties, including higher bioavail.. | ||
Dec 31 |
et al., Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2024.12.032 | A retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years |
Retrospective 5,131 elderly hospitalized COVID-19 patients in China showing lower mortality with azvudine compared to paxlovid. There was no significant difference in composite disease progression. Safety analysis showed azvudine had a lo.. | ||
Dec 31 |
et al., Trends in Food Science & Technology, doi:10.1016/j.tifs.2024.104864 | Bioactive compounds,quercetin, curcumin and β-glucan,regulate innate immunity via the gut-liver-brain axis |
Review of how bioactive compounds quercetin, curcumin, and β-glucan regulate innate immunity through the gut-liver-brain axis, with focus on COVID-19. Authors describe how SARS-CoV-2 infection triggers excessive immune activation and cyto.. | ||
Dec 30 |
et al., Journal of Neonatal Surgery, doi:10.47338/jns.v13.1432 | Antiviral Efficacy of Iota-Carrageenan Lozenges in Treating Acute Viral Pharyngitis: A Randomized Controlled Study |
Non-COVID-19 RCT 180 patients with acute viral pharyngitis, predominantly caused by human rhinovirus (HRV), showing symptom improvement and viral load reduction with iota-carrageenan lozenges compared to placebo. Patients receiving lozeng.. | ||
Dec 30 |
et al., BMC Nutrition, doi:10.1186/s40795-024-00983-2 | The relationship between healthy eating index and Mediterranean diet adherence score with inflammatory indices and disease severity: a case-control study of hospitalized COVID-19 patients |
Case-control study of 150 hospitalized COVID-19 patients and 150 controls, showing significantly lower healthy eating index (HEI) and Mediterranean diet adherence scores (MDS) for COVID-19 patients. Lower HEI and MDS scores were also asso.. | ||
Dec 30 |
et al., Nutrients, doi:10.3390/nu17010110 | Relationship Between Vitamin D Levels with In-Hospital Complications and Morphofunctional Recovery in a Cohort of Patients After Severe COVID-19 Across Different Obesity Phenotypes |
Prospective observational study of 94 postcritical COVID-19 patients showing that higher vitamin D levels were associated with fewer complications, shorter hospital and ICU stays, and improved morphofunctional recovery. Vitamin D deficien.. | ||
Dec 26 |
et al., European Journal of Medical Research, doi:10.1186/s40001-024-02220-9 | Azvudine efficacy in reducing mortality in COVID-19 patients |
35% lower mortality (p=0.05). Retrospective 2,862 hospitalized COVID-19 patients in China showing lower mortality with azvudine treatment, with greater efficacy for severe and critical patients. | ||
Dec 25 |
et al., Pulmonary Therapy, doi:10.1007/s41030-024-00284-w | Real-World Effectiveness of Bebtelovimab Versus Nirmatrelvir/Ritonavir in Outpatients with COVID-19 |
Retrospective 5,827 matched pairs of non-hospitalized COVID-19 patients showing no significant differences between bebtelovimab and paxlovid treatment. Authors do not exclude patients with contraindications for paxlovid. | ||
Dec 22 |
et al., Hemodialysis International, doi:10.1111/hdi.13194 | Associations of vitamin D levels and clinical parameters with COVID‐19 infection, severity and mortality in hemodialysis patients: A cohort study |
82% lower mortality (p=0.15) and 96% lower severe cases (p=0.01). Retrospective 198 hemodialysis patients in China showing vitamin D deficiency associated with an increased risk of COVID‐19 severity. | ||
Dec 20 |
et al., Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2024.1476603 | Longitudinal ozone exposure and SARS-CoV-2 infection in late pregnancy: a retrospective cohort study |
40% fewer cases (p=0.23). Retrospective 600 pregnant women in an urban area of China showing a significantly lower risk of SARS-CoV-2 infection in late pregnancy with higher gestational ozone exposure levels. Ozone exposure, driven by photochemical reactions, is s.. | ||
Dec 18 |
et al., Viruses, doi:10.3390/v16121938 | Metformin in Antiviral Therapy: Evidence and Perspectives |
Review of metformin as a promising broad-spectrum antiviral agent, focusing on its potential for treating SARS-CoV-2 infection. Authors highlight metformin's ability to activate AMPK and inhibit mTOR signaling, which can help reduce hyper.. |
We aim to cover the most promising early treatments for
COVID-19. We use pre-specified effect extraction criteria that prioritizes
more serious outcomes, for details see methods. For specific
outcomes and different treatment stages see the individual pages. Not all
treatments are covered here, effectiveness has been reported for many other treatments in studies.
Of the 5,255 studies,
2,516 present results comparing with a control group,
2,305 are treatment studies, and
211 analyze outcomes based on serum levels. There are
99 animal studies,
192 in silico studies,
349 in vitro studies,
414 reviews,
and 229 meta analyses.
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.